Intellia Therapeutics Presents Data On Redosing With In Vivo CRISPR Therapy; 55 mg NTLA-2001 Dose Shows 90% Median Reduction In Serum TTR At Day 28; Well Tolerated Across All Patients; Potential Redosing Advantage For Future Therapies
Portfolio Pulse from Benzinga Newsdesk
Intellia Therapeutics presented data showing that a 55 mg dose of NTLA-2001 led to a 90% median reduction in serum TTR at day 28 in patients, demonstrating the potential for redosing with in vivo CRISPR therapy. The dose was well tolerated across all patients, indicating a potential advantage for future therapies.
June 25, 2024 | 7:32 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
While the article focuses on Intellia Therapeutics, the positive data on in vivo CRISPR therapy could have a positive spillover effect on other companies in the CRISPR space, including CRISPR Therapeutics.
The success of Intellia's in vivo CRISPR therapy could enhance the overall perception and potential of CRISPR-based therapies, indirectly benefiting CRISPR Therapeutics.
CONFIDENCE 70
IMPORTANCE 60
RELEVANCE 50
POSITIVE IMPACT
Intellia Therapeutics' data on NTLA-2001 shows a 90% median reduction in serum TTR at day 28 with a 55 mg dose, well tolerated across all patients. This demonstrates the potential for redosing with in vivo CRISPR therapy, which could be advantageous for future therapies.
The positive clinical data showing significant reduction in serum TTR and good tolerance across patients suggests strong potential for NTLA-2001 and future therapies using Intellia's platform. This is likely to boost investor confidence and positively impact NTLA's stock price.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100